

Special Issue

Narrow-Spectrum Antibiotics: How Can They Help in the Fight against Antimicrobial Resistance and How Can We Get More of Them?

Message from the Guest Editor

As guest editor I'd like to bring your attention to an upcoming issue devoted to issues surrounding the production and use of narrow spectrum antibiotics. The intention of the special issue to do the following:

- Define the qualities of narrow spectrums and the biological and epidemiological advantages that can be achieved in promoting their development and use over those with a broader spectrum of activity.
- Summarize our experience with existing narrow spectrums will be explored at the evolutionary and clinical level.
- Explore the ways in which we can optimally encourage the necessary research and development of such products, looking across the variety of strategies, comparing the attributes of schemes required to bring them to market.
- Examine the role of such products within stewardship policies and how we can optimize their use to prolong the efficacy of antibiotics overall.

We hope that you will find this issue of interest.

Keywords: Antimicrobial resistance; Narrow-spectrum; Antibiotics

Guest Editor

Dr. Chantal M. Morel

Faculty of Medicine, University of Geneva, Rue Michel-Servet 1, 1206 Geneva, Switzerland

Deadline for manuscript submissions

closed (30 May 2020)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/31488

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)